Citations

Clear

6 citation(s) found for "Snow, Karen".

Bioelectronic Sensor Technology for Detection of Cystic Fibrosis and Hereditary Hemochromatosis Mutations
Bernacki, Susan H. , Farkas, Daniel H., Shi, Wenmei, Chan, Vivian, Liu, Yenbou, Beck, Jeanne C., Bailey, Karen Snow, Pratt, Victoria M. , Monaghan, Kristin G. , Matteson, Karla J., Schaefer, Frederick V., Friez, Michael J., Shrimpton, Antony E., Stenzel, Timothy T. , Chan, Vivian

Mayo Clinic

Archives of Pathology & Laboratory Medicine | February 8, 2021 | Volume: 127 | Issue: 12 | Pages: 1565-1572

10.5858/2003-127-1565-bstfdo | PMID 14632577 Get It

Abstract Context. —Bioelectronic sensors, which combine microchip and biological components, are an emerging technology in clinical diagnostic testing. An electronic detection platform using DNA biochip technology (eSensor) is under development for molecular diagnostic applications. Owing to the novelty of these devices, demonstrations of their successful use in practical diagnostic applications are limited. Objective. —To assess the performance of the eSensor bioelectronic method in the validation of 6 Epstein-Barr virus–transformed blood lymphocyte cell lines with clinically important mutations for use as sources of genetic material for positive controls in clinical molecular genetic testing. Two cell lines carry mutations in the CFTR gene (cystic fibrosis), and 4 carry mutations in the HFE gene (hereditary hemochromatosis). Design. —Samples from each cell line were sent for genotype determination to 6 different molecular genetic testing facilities, including the laboratory developing the DNA biochips. In addition to the bioelectronic method, at least 3 different molecular diagnostic methods were used in the analysis of each cell line. Detailed data were collected from the DNA biochip output, and the genetic results were compared with those obtained using the more established methods. Results. —We report the successful use of 2 applications of the bioelectronic platform, one for detection of CFTR mutations and the other for detection of HFE mutations. In all cases, the results obtained with the DNA biochip were in concordance with those reported for the other methods. Electronic signal output from the DNA biochips clearly differentiated between mutated and wild-type alleles. This is the first report of the use of the cystic fibrosis detection platform. Conclusions. —Bioelectronic sensors for the detection of disease-causing mutations performed well when used in a “real-life” situation, in this case, a validation study of positive control blood lymphocyte cell lines with mutations of public health importance. This study illustrates the practical potential of emerging bioelectronic DNA detection technologies for use in current molecular diagnostic applications.
Evaluation of Microchip Electrophoresis as a Molecular Diagnostic Method for Duchenne Muscular Dystrophy
Snow, Karen, Landers, James P. , Ferrance, Jerome P.

Mayo Clinic

Clinical Chemistry | January 24, 2020 | Volume: 48 | Issue: 2 | Pages: 380-383

10.1093/clinchem/48.2.380 Get It

Molecular Diagnostics on Microfabricated Electrophoretic Devices: From Slab Gel- to Capillary- to Microchip-based Assays for T- and B-Cell Lymphoproliferative Disorders
Munro, Nicole J., Kant, Jeffrey A., Landers, James P. , Snow, Karen

Mayo Clinic

Clinical Chemistry | January 23, 2020 | Volume: 45 | Issue: 11 | Pages: 1906-1917

10.1093/clinchem/45.11.1906 Get It

Abstract Background: Current methods for molecular-based diagnosis of disease rely heavily on modern molecular biology techniques for interrogating the genome for aberrant DNA sequences. These techniques typically include amplification of the target DNA sequences followed by separation of the amplified fragments by slab gel electrophoresis. As a result of the labor-intensive, time-consuming nature of slab gel electrophoresis, alternative electrophoretic formats have been developed in the form of capillary electrophoresis and, more recently, multichannel microchip electrophoresis. Methods: Capillary electrophoresis was explored as an alternative to slab gel electrophoresis for the analysis of PCR-amplified products indicative of T- and B-cell malignancies as a means of defining the elements for silica microchip-based diagnosis. Capillary-based separations were replicated on electrophoretic microchips. Results: The microchip-based electrophoretic separation effectively resolved PCR-amplified fragments from the variable region of the T-cell receptor-γ gene (150–250 bp range) and the immunoglobulin heavy chain gene (80–140 bp range), yielding diagnostically relevant information regarding the presence of clonal DNA populations. Although hydroxyethylcellulose provided adequate separation power, the need for a coated microchannel for effective resolution necessitated additional preparative steps. In addition, preliminary data are shown indicating that polyvinylpyrrolidone may provide an adequate matrix without the need for microchannel coating. Conclusions: Separation of B- and T-cell gene rearrangement PCR products on microchips provides diagnostic information in dramatically reduced time (160 s vs 2.5 h) with no loss of diagnostic capacity when compared with current methodologies. As illustrated, this technology and methodology holds great potential for extrapolation to the abundance of similar molecular biology-based techniques.
Genetically Characterized Positive Control Cell Lines Derived from Residual Clinical Blood Samples
Bernacki, Susan H. , Beck, Jeanne C., Stanković, Ana , Williams, Laurina O. , Amos, Jean, Snow-Bailey, Karen, Farkas, Daniel H., Friez, Michael J., Hantash, Feras, Matteson, Karla J., Monaghan, Kristin G. , Muralidharan, Kasinathan, Pratt, Victoria M. , Prior, Thomas W., Richie, Kristy L., Levin, Barbara C., Rohlfs, Elizabeth M., Schaefer, Frederick V., Shrimpton, Antony E., Spector, Elaine , Stolle, Catherine A., Strom, Charles M. , Thibodeau, Stephen N. , Cole, Eugene C., Goodman, Barbara K. , Stenzel, Timothy T.

Mayo Clinic

Clinical Chemistry | September 16, 2005 | Volume: 51 | Issue: 11 | Pages: 2013-2024

10.1373/clinchem.2005.048694 | PMID 16166172 Get It

AbstractBackground: Positive control materials for clinical diagnostic molecular genetic testing are in critically short supply. High-quality DNA that closely resembles DNA isolated from patient specimens can be obtained from Epstein–Barr virus (EBV)–transformed peripheral blood lymphocyte cell lines. Here we report the development of a process to (a) recover residual blood samples with clinically important mutations detected during routine medical care, (b) select samples likely to provide viable lymphocytes for EBV transformation, (c) establish stable cell lines and confirm the reported mutation(s), and (d) validate the cell lines for use as positive controls in clinical molecular genetic testing applications.Methods: A network of 32 genetic testing laboratories was established to obtain anonymous, residual clinical samples for transformation and to validate resulting cell lines for use as positive controls. Three panel meetings with experts in molecular genetic testing were held to evaluate results and formulate a process that could function in the context of current common practices in molecular diagnostic testing.Results: Thirteen laboratories submitted a total of 113 residual clinical blood samples with mutations for 14 genetic disorders. Forty-one EBV-transformed cell lines were established. Thirty-five individual point and deletion mutations were shown to be stable after 20 population doublings in culture. Thirty-three cell lines were characterized for specific mutations and validated for use as positive controls in clinical diagnostic applications.Conclusions: A process for producing and validating positive control cell lines from residual clinical blood samples has been developed. Sustainable implementation of the process could help alleviate the current shortage of positive control materials.
Detection of Sequence Variations in the Adenomatous Polyposis Coli ( APC ) Gene Using Denaturing High-Performance Liquid Chromatography
Hegde, Madhuri , Fawkner, Matthew, Chong, Belinda , Love, Donald R. , Su, Li , Lynch, Patrick M. , Wu, Guohao , Wu, Wei , Snow, Karen , Richards, C. Sue

Mayo Clinic

Genetic Testing | July 26, 2002 | Volume: 5 | Issue: 4 | Pages: 281-290

10.1089/109065701753617408 | PMID 11960572 Get It

Null Alleles at the Huntington Disease Locus: Implications for Diagnostics and CAG Repeat Instability
Williams, Liam , Hegde, Madhuri , Nagappan, Radhika, Faull, Richard L. M. , Giles, Jennie, Winship, Ingrid , Snow, Karen, Love, Donald R. , Winship, Ingrid M

Mayo Clinic

Genetic Testing | July 26, 2002 | Volume: 4 | Issue: 1 | Pages: 55-60

10.1089/109065700316480 | PMID 10794362 Get It